Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/13/1121   
Active ingredient: Lenvatinib
Indication: Treatment of papillary thyroid cancer
Sponsor: Eisai Europe Limited
European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Lenvima on 28/05/2015 with the number EU/1/15/1002

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/04/2013 Orphan designation EMA/OD/173/12 (2013)2558 of 26/04/2013